These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 27786155

  • 1. Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
    Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Sophonphan J, Ananworanich J, Puthanakit T, Bone-D study group.
    Antivir Ther; 2017; 22(6):471-479. PubMed ID: 27786155
    [Abstract] [Full Text] [Related]

  • 2. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW, PREPARE (Preventing Progression of Adipose Tissue Redistribution) Investigators.
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
    [Abstract] [Full Text] [Related]

  • 3. Adverse bone health and abnormal bone turnover among perinatally HIV-infected Asian adolescents with virological suppression.
    Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, Sophonphan J, Sohn AH, Ananworanich J, Puthanakit T, Bone-D Study Group.
    HIV Med; 2017 Apr; 18(4):235-244. PubMed ID: 27477214
    [Abstract] [Full Text] [Related]

  • 4. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [Abstract] [Full Text] [Related]

  • 5. Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe.
    Rukuni R, Rehman AM, Mukwasi-Kahari C, Madanhire T, Kowo-Nyakoko F, McHugh G, Filteau S, Chipanga J, Simms V, Mujuru H, Ward KA, Ferrand RA, Gregson CL.
    Lancet Child Adolesc Health; 2021 Aug; 5(8):569-581. PubMed ID: 34139202
    [Abstract] [Full Text] [Related]

  • 6. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams.
    Antivir Ther; 2018 Aug; 23(7):623-628. PubMed ID: 30260797
    [Abstract] [Full Text] [Related]

  • 7. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
    Viganò A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C, Salvini F, Cellini M, Tamburrini E, Puzzovio M, Zuccotti GV.
    Antivir Ther; 2011 Aug; 16(8):1259-66. PubMed ID: 22155907
    [Abstract] [Full Text] [Related]

  • 8. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT.
    HIV Clin Trials; 2015 Aug; 16(2):66-71. PubMed ID: 25872972
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Human Immunodeficiency Virus Infection With Tenofovir Disoproxil Fumarate-Containing Antiretrovirals Maintains Low Bone Formation Rate, But Increases Osteoid Volume on Bone Histomorphometry.
    Ramalho J, Martins CSW, Galvão J, Furukawa LN, Domingues WV, Oliveira IB, Dos Reis LM, Pereira RM, Nickolas TL, Yin MT, Eira M, Jorgetti V, Moyses RM.
    J Bone Miner Res; 2019 Sep; 34(9):1574-1584. PubMed ID: 31269294
    [Abstract] [Full Text] [Related]

  • 10. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team.
    Clin Infect Dis; 2018 Jan 06; 66(2):220-228. PubMed ID: 29020329
    [Abstract] [Full Text] [Related]

  • 11. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM, Wattanachanya L, Apornpong T, Jantrapakde J, Avihingsanon A, Kerr SJ, Teeratakulpisarn N, Jadwattanakul T, Chaiwatanarat T, Buranasupkajorn P, Ramautarsing R, Phanuphak N, Sunthornyothin S, Ruxrungtham K, Phanuphak P, TNT 003.1 study team.
    PLoS One; 2020 Jan 06; 15(3):e0230368. PubMed ID: 32210458
    [Abstract] [Full Text] [Related]

  • 12. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.
    Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW, Adolescent Medicine Trials Network for HIV/AIDS Interventions.
    AIDS Res Hum Retroviruses; 2019 Aug 06; 35(8):746-754. PubMed ID: 31115244
    [Abstract] [Full Text] [Related]

  • 13. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.
    Giacomet V, Maruca K, Ambrosi A, Zuccotti GV, Mora S.
    Int J Antimicrob Agents; 2017 Sep 06; 50(3):365-370. PubMed ID: 28689877
    [Abstract] [Full Text] [Related]

  • 14. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K, Songtaweesin WN, Tepmongkol S, Wongharn P, Kawichai S, Suponsilchai V, Anugulruengkitt S, Puthanakit T, CE-PID - IHRI Adolescent Study Team.
    J Int AIDS Soc; 2020 Oct 06; 23(10):e25624. PubMed ID: 33040465
    [Abstract] [Full Text] [Related]

  • 15. Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.
    Unsal AB, Mattingly AS, Jones SE, Purdy JB, Reynolds JC, Kopp JB, Hazra R, Hadigan CM.
    J Clin Endocrinol Metab; 2017 Aug 01; 102(8):2896-2904. PubMed ID: 28531309
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K.
    Pediatr Infect Dis J; 2015 Apr 01; 34(4):392-7. PubMed ID: 25760566
    [Abstract] [Full Text] [Related]

  • 17. Hypovitaminosis D and hyperparathyroidism: effects on bone turnover and bone mineral density among perinatally HIV-infected adolescents.
    Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, Sophonphan J, Ananworanich J, Puthanakit T, Bone-D Study Group.
    AIDS; 2016 Apr 24; 30(7):1059-67. PubMed ID: 26807972
    [Abstract] [Full Text] [Related]

  • 18. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda.
    Kiweewa Matovu F, Kiwanuka N, Nabwana M, Scholes D, Musoke P, Glenn Fowler M, Beksinska ME, Pettifor JM, Brown TT, BONE: CARE Study Team.
    Lancet Glob Health; 2022 May 24; 10(5):e694-e704. PubMed ID: 35427526
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
    Della Negra M, De Carvalho AP, De Aquino MZ, Pinto JA, Da Silva MT, Andreatta KN, Graham B, Liu YP, Quirk EK.
    Pediatr Infect Dis J; 2015 Apr 24; 34(4):398-405. PubMed ID: 25599284
    [Abstract] [Full Text] [Related]

  • 20. The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
    Alvarez E, Campbell L, Tinago W, Garcia-Leon A, Walsh I, Brady JJ, Burling K, Noe S, Neuville MF, Jouret F, Jamshidian F, Graham H, Rhee M, Mallon PW, Post FA.
    Antivir Ther; 2022 Aug 24; 27(4):13596535221094898. PubMed ID: 36000318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.